{"slug":"idh","tag":"idh","variants":["idh"],"description":"No description yet","count":4,"kinds":{"person":2,"biomarker":2},"related":[{"slug":"biomarker","tag":"biomarker","shared":2},{"slug":"aml","tag":"aml","shared":1},{"slug":"early-phase","tag":"early-phase","shared":1},{"slug":"glioma","tag":"glioma","shared":1},{"slug":"menin","tag":"menin","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1}],"records":[{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","tldr":"Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma."},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","tldr":"Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia."},{"id":"idh1-r132","kind":"biomarker","name":"IDH1 R132 mutation","route":"/biomarkers/idh1-r132/","tldr":"IDH1 R132 mutations turn a metabolic enzyme into a producer of the oncometabolite 2-HG. They define lower-grade gliomas and occur in acute myeloid leukaemia and bile duct cancer, each with an approved IDH1 inhibitor."},{"id":"idh2-mutation","kind":"biomarker","name":"IDH2 mutation (R140 and R172)","route":"/biomarkers/idh2-mutation/","tldr":"IDH2 mutations at codons 140 and 172 do the same job as IDH1 R132, producing 2-HG. Enasidenib is approved for relapsed AML with them, and vorasidenib for grade 2 gliomas with either IDH gene mutated."}]}